ADC Development Services Targeting STEAP1

Antibody-drug conjugates (ADCs) as a type of effective and well-tolerated antitumor therapeutic agent have attracted great attention since the approval of several ADCs. Currently, various ADCs are in preclinical or clinical development for different cancer treatments. Creative Biolabs provides a wide range of ADCs development services targeting all kinds of biomarkers such as the STEAP1. Our services include antibody production, linker-payload synthesis, and effective bio-conjugation. Our scientists are pleased to offer customized ADCs services based on traditional strategy as well as novel conjugation strategy.

Introduction of STEAP1

STEAP1 is a 6-transmembrane protein encoded by the STEAP1 gene localized on chromosome 7q21, which belongs to the STEAP family. It contains six transmembrane domains, three extracellular domains and two intracellular loops. STEAP1 is mainly expressed in prostate tissue and also in normal tissues. It plays an important role in the tight junctions and gap junctions serving as an ion channel or transporter protein. It also involves in cell adhesion, intercellular communication, cell proliferation and anti-apoptosis. STEAP1 is much more highly expressed in tumor cells than in normal tissues and its expression is associated with several malignant cancers, including prostate cancer, head and neck squamous cell carcinoma, Ewing family tumors, breast cancer, and melanoma. Thus, STEAP1 is considered as a promising and useful target in cancer therapy.

Fig.1 STEAP gene organization, mRNA transcripts and predicted protein structure.

Anti-STEAP1 ADC in Prostate Cancer

STEAP1 as a biomarker has been used in ADC development for the prostate cancer treatment. Vandortuzumab vedotin (also known as RG7450 or DSTP3086S) is an ADC targeting STEAP1, which is composed of a humanized anti-STEAP1 monoclonal antibody linked to the potent anti-mitotic drug monomethyl auristatin E (MMAE) through a protease-cleavable valine-alanine linker. Once the ADC binds to the target, which then can be internalized and to release the payload and cause the tumor cell death. Vandortuzumab vedotin is investigated in the Phase 1 clinical trial currently. Clinical trials demonstrated that vandortuzumab vedotin has an acceptable safety and tolerability profile with minimal adverse side effects. Besides, anti-tumor activity results showed that the ADC has acceptable pharmacokinetics in prostate cancer. Therefore, vandortuzumab vedotin is believed to be a viable therapeutic agent to treat metastatic castration-resistant prostate cancer.

Fig.2 Structures of vandortuzumab vedotin. (Lu, 2015)

What Can We Do for You?

As a leading service provider in the field of novel therapeutics development, Creative Biolabs has focused on the antibody and ADCs design and preparation for more than ten years. Supported by our advanced platforms and rich expertise, Creative Biolabs provides comprehensive ADCs development services against different biomarkers including the STEAP1. Our services range from antibody and linker-payload production to ADC conjugation and characterization. We succeed with excellence and confidence to meet your demand for creating effective and cost-effective ADCs.

Our ADCs development services including:

• ADC Antibody Screening
• DrugLnk™ Custom Synthesis
• Antibody Design and Conjugation
• ADC in vitro Analysis
• ADC in vivo Analysis

Reference

1. Lu, D.; et al. Semi-mechanistic multiple-analyte pharmacokinetic model for an antibody-drug-conjugate in cynomolgus monkeys. Pharmaceutical research. 2015, 32(6): 1907-1919.

For Research Use Only. NOT FOR CLINICAL USE.